Actively Recruiting
Uncover Mechanisms Underlying the Development of Chronic Lung Sequelae Post COVID-19
Led by Mayo Clinic · Updated on 2026-05-07
67
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating why some people experience lasting effects like shortness of breath and fatigue after severe COVID-19 infection. The study focuses on people who had severe COVID-19 requiring hospitalization and those with mild cases who fully recovered. Its goal is to understand the clinical, imaging, immune, molecular, and viral factors linked to long-term lung problems after COVID-19. Participants will visit the Mayo Clinic three times over about a year: around 2-3 months, 6 months, and 12 months after their COVID-19 diagnosis. During these visits, they will undergo lung imaging with CT scans, pulmonary function tests, heart electrical activity checks with ECG, and 6-minute walk tests. Bronchoscopies with bronchoalveolar lavages (BAL) will be done at the first and third visits to collect lung samples. Blood samples will also be collected at all visits to study immune and molecular changes over time. Participants will complete quality of life questionnaires and receive comprehensive clinical evaluations at each visit. Researchers will analyze lung images, lung function, and biological samples to identify markers related to chronic lung conditions post-COVID-19. The study lasts about 12 months per participant, with ongoing monitoring of lung health and symptoms. The main outcome is to uncover traits linked to long-term lung problems following COVID-19 infection.
CONDITIONS
Brief Title
A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older at screening
- PCR confirmed COVID-19 illness
- For the sequelae group: hospitalization for COVID-19 and no prior history of interstitial lung disease or significant lung disease
- Severity of illness categorized by oxygen needs or ICU admission
- For the recovery group: mild or asymptomatic COVID-19 not requiring hospitalization
- No ongoing respiratory or systemic symptoms for recovery group
You will not qualify if you...
- Unable to provide informed consent
- Pre-existing interstitial lung disease or chronic lung disease
- Current cigarette smoking, vaping, or inhalation use
- Immunocompromised due to certain medications
- More than 20 pack-year smoking history
- Chemotherapy or radiation therapy in the last two years
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 12 months
Participants undergo comprehensive clinical evaluation, symptom characterization, lung CT imaging, pulmonary function tests, and quality of life questionnaires. Blood samples are collected at each visit, and bronchoscopy with bronchoalveolar lavage (BAL) is performed at visits 1 and 3.
3 visits at approximately 2-3 months, 6 months, and 12 months post COVID-19 diagnosis (in-person)
Trial Site Locations
Total: 1 location
1
Mayo Clinic Minnesota
Rochester, Minnesota, United States, 55905
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here